Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
paclitaxel protein-bound + liposomal doxorubicin
- Development stage
- Unknown
- Lead developer
- Bristol Myers Squibb
- Modality
- Nanoparticles → Drug Delivery Systems, Small Molecules
- Administration
- Intravenous
01
Overview
A combination chemotherapy regimen consisting of paclitaxel protein-bound (nab-paclitaxel) and liposomal doxorubicin. Paclitaxel protein-bound is a formulation where paclitaxel particles are bound to human albumin, eliminating the need for Cremophor solvent used in conventional paclitaxel. Liposomal doxorubicin encapsulates doxorubicin in liposomes to reduce cardiotoxicity. This combination leverages complementary mechanisms of action: paclitaxel disrupts microtubular networks essential for cell division, while doxorubicin damages DNA. The combination shows synergistic effects with enhanced bioavailability, circulation time, and targeted delivery to tumor tissues.
- Brand names
- DoxilAbraxane
- Other names
- nab-paclitaxel + liposomal doxorubicinwNP/wNPLDalbumin-bound paclitaxel + liposomal doxorubicin
02
Targets
MicrotubuleTOP2A (DNA topoisomerase II)DNA
Beyond the preview
Go deeper on paclitaxel protein-bound + liposomal doxorubicin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on paclitaxel protein-bound + liposomal doxorubicin.